Influx Healthtech Begins Tablet Manufacturing At New Kolgaon Facility

Image Source: Chittorgarh

Influx Healthtech Ltd has received regulatory clearance from FSSAI to begin tablet manufacturing operations at its newly rented facility in Kolgaon. The move marks a strategic expansion in its nutraceutical and pharmaceutical production capabilities, reinforcing its commitment to innovation, compliance, and nationwide distribution.

New facility signals production scale-up

Influx Healthtech Ltd has announced the commencement of tablet manufacturing operations at its newly established rented facility in Kolgaon, Maharashtra. The company confirmed that it has secured the necessary license from the Food Safety and Standards Authority of India (FSSAI), enabling full-scale production of nutraceutical and pharmaceutical tablets.

The Kolgaon facility is equipped with advanced machinery and quality control systems, aligning with Influx’s goal to meet growing demand across India and international markets.

Regulatory approval boosts credibility

The FSSAI license, granted under Form II approval, validates the company’s compliance with national food safety and manufacturing standards. This regulatory milestone allows Influx to produce a range of formulations, including magnesium glycinate tablets, which are part of its expanding product portfolio.

The license also enhances the company’s ability to pursue third-party manufacturing contracts and expand its footprint in the health and wellness sector.

Key highlights of the announcement

- Influx Healthtech Ltd begins tablet manufacturing at Kolgaon facility
- Facility is fully licensed by FSSAI for nutraceutical production
- Operations will include magnesium glycinate and other formulations
- Facility supports contract manufacturing and export potential
- Expansion aligns with company’s pan-India and global growth strategy
- Advanced machinery and GMP-compliant systems installed

Strategic outlook and industry impact

Influx Healthtech’s expansion into Kolgaon reflects its long-term strategy to scale operations and diversify its product offerings. With certifications including GMP, HACCP, ISO 22000, and Halal, the company is well-positioned to serve both domestic and international clients. The new facility is expected to increase production capacity, reduce lead times, and support innovation in tablet-based health solutions.

Industry analysts view this development as a positive step toward strengthening India’s nutraceutical manufacturing ecosystem.

Sources: Influx Healthtech, MarketScreener, FSSAI India